Haloperidol is a typical antipsychotic medication used to treat schizophrenia, the tics of Tourette syndrome, bipolar mania, delirium, agitation, acute psychosis and hallucinations from alcohol withdrawal, generally producing effects within thirty to sixty minutes. It works chiefly through high-affinity antagonism of dopamine D2 receptors, with slow receptor dissociation, giving it effects comparable to the older phenothiazine antipsychotics. Paul Janssen discovered haloperidol in 1958 at his company, Janssen Pharmaceutica in Belgium, where clinical trials began that same year; the Food and Drug Administration approved it on April 12, 1967, and McNeil Laboratories subsequently marketed it in the United States under the brand name Haldol. It remains the most commonly used typical antipsychotic and appears on the World Health Organization's List of Essential Medicines.
Facts
Drug ClassTypical (first-generation) antipsychotic of the butyrophenone class. 1 Mechanism of ActionHigh-affinity antagonist of dopamine D2 receptors with slow receptor dissociation kinetics. 1 Approved UseTreatment of schizophrenia, Tourette syndrome tics, bipolar mania, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal. 1 First Approved / Isolated Year Significant RiskMovement disorders including tardive dyskinesia and akathisia, which may be permanent; also neuroleptic malignant syndrome and QT interval prolongation, particularly with intravenous use. 1 Classification
Approval Status ATC ClassSourced to the subject's own account Route of Administration WHO Essential MedicineSourced to the subject's own account Connections
Treats
Source Haloperidol (Wikipedia)
Sources
1. Haloperidol (Wikipedia)
Wikimedia FoundationLead section
Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal.
Infobox, drug class
Typical antipsychotic
Pharmacology section
Haloperidol is a typical butyrophenone-type antipsychotic that exhibits high-affinity dopamine D2 receptor antagonism and slow receptor dissociation kinetics.
Lead section, adverse effects
Haloperidol may result in movement disorders such as tardive dyskinesia, and akathisia, both of which may be permanent. Neuroleptic malignant syndrome and QT interval prolongation may occur, the latter particularly with IV administration.
History section
Haloperidol was approved by the U.S. Food and Drug Administration (FDA) on 12 April 1967; it was later marketed in the U.S. and other countries under the brand name Haldol by McNeil Laboratories.
https://en.wikipedia.org/wiki/Haloperidol, lead section
and hallucinations from alcohol withdrawal. It may be used by mouth or injection into a muscle or a vein. Haloperidol typically works within 30 to 60 minutes. A long-acting formulation may be used as an injection every four weeks for people with schizophrenia
- Regulatory approval status
Treats: Schizophrenia, Lead section, indication
Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal.
View the Source 2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code NQuote, First-level anatomical group codes, Code N
Nervous system
3. Wikipedia
Wikipedia contributors, Wikimedia Foundation
4. WHO Model List of Essential Medicines (Wikipedia)
WikipediaWHO Model List of Essential Medicines, Medicines used in psychotic disorders sectionQuote, WHO Model List of Essential Medicines, Medicines used in psychotic disorders section
Haloperidol
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.